Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Times Interest Earned (2019 - 2025)

BridgeBio Pharma's Times Interest Earned history spans 7 years, with the latest figure at $3.63 for Q4 2025.

  • For Q4 2025, Times Interest Earned rose 134.59% year-over-year to $3.63; the TTM value through Dec 2025 reached -$9.86, down 51.25%, while the annual FY2025 figure was -$9.86, 51.25% down from the prior year.
  • Times Interest Earned for Q4 2025 was $3.63 at BridgeBio Pharma, up from -$12.37 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $3.63 in Q4 2025 and bottomed at -$17.2 in Q1 2021.
  • The 5-year median for Times Interest Earned is -$7.71 (2023), against an average of -$7.35.
  • The largest YoY upside for Times Interest Earned was 134.59% in 2025 against a maximum downside of 17047.93% in 2025.
  • A 5-year view of Times Interest Earned shows it stood at -$10.94 in 2021, then skyrocketed by 40.92% to -$6.46 in 2022, then plummeted by 35.4% to -$8.75 in 2023, then dropped by 19.98% to -$10.5 in 2024, then skyrocketed by 134.59% to $3.63 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Times Interest Earned are $3.63 (Q4 2025), -$12.37 (Q3 2025), and -$3.57 (Q2 2025).